Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 2/20 | 0.50 |
| ▸ | CCR5 | P51681 | 2/20 | 0.50 |
| ▸ | NR3C1 | P04150 | 7/20 | 0.48 |
| ▸ | LIMK2 | P53671 | 2/20 | 0.46 |
| ▸ | PDE4A | P27815 | 3/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5961551 | 0.91 | CCR2 (0.49) | CCR2CCR5NR3C1LIMK2PDE4A | |
| SCHEMBL7171888 | 0.91 | NR3C1 (0.50) | CCR2CCR5NR3C1LIMK2PDE4A | |
| SCHEMBL7077934 | 0.86 | NR3C1 (0.45) | CCR2CCR5NR3C1PDE4APDE4B | |
| SCHEMBL5961542 | 0.84 | CCR2 (0.47) | CCR2CCR5NR3C1LIMK2PDE4A | |
| SCHEMBL5961433 | 0.77 | CCR2 (0.59) | CCR2CCR5NR3C1PDE4APDE4B | |
| SCHEMBL5961445 | 0.75 | CCR2 (0.53) | CCR2CCR5NR3C1PDE4APDE4B | |
| SCHEMBL5961511 | 0.74 | NR3C1 (0.47) | CCR2CCR5NR3C1 | |
| SCHEMBL7078715 | 0.74 | CCR2 (0.56) | CCR2CCR5NR3C1PDE4APDE4B | |
| SCHEMBL5961580 | 0.73 | NR3C1 (0.51) | CCR2CCR5NR3C1PDE4APDE4B | |
| SCHEMBL7078711 | 0.72 | CCR2 (0.50) | CCR2CCR5NR3C1PDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6992086-B2 | Antagonists of MCP-1 function and methods of use thereof | TELIK, INC. (US) | 2006-01-31 | — | — | US | disclosed |
| US-20040077680-A1 | Antagonists of MCP-1 function and methods of use thereof | TELIK, INC. | 2004-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077680-A1 | Antagonists of MCP-1 function and methods of use thereof | CCR2, CCR1, CCL2 | CCR2 1/4885CCR5 4/4885NR3C1 673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.